Nebivolol Monotherapy for Patients With Systolic Stage II Hypertension: Results of a Randomized, Placebo-Controlled Trial

Clinical Therapeutics

Volumn 35, Issue 2, 2013, Pages 142-152

  Lewin, Andrew ^a   Punzi, Henry ^b   Luo, Xiaohui ^c   Stapff, Manfred ^c  

^a NATIONAL RESEARCH INSTITUTE   (United States)

^b Trinity Hypertension Research Institute   (United States)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEBIVOLOL; PLACEBO;

ADULT; AFRICAN AMERICAN; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BRADYCARDIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HISPANIC; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MORTALITY; MULTICENTER STUDY; MYOFASCIAL PAIN; PERIPHERAL EDEMA; PHASE 4 CLINICAL TRIAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; THORAX PAIN; WEIGHT GAIN;

ADOLESCENT; ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84873585185     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.015     Document Type: Article

References (34)

1. Population estimates, 2010 US Census Bureau, Accessed September 7, 2011. http://www.census.gov/population/www/socdemo/age/age_sex_2010.html.
2. Egan B.M., Zhao Y., Axon R.N. US Trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010, 303:2043-2050.
3. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252.
4. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
5. Benetos A., Thomas F., Bean K., et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002, 162:577-581.
6. Biskupiak J.E., Kim J., Phatak H., Wu D. Prevalence of high-risk cardiovascular conditions and the status of hypertension management among hypertensive adults 65 years and older in the United States: analysis of a primary care electronic medical records database. J Clin Hypertens (Greenwich) 2010, 12:935-944.
7. Calhoun D.A. Resistant or difficult-to-treat hypertension. J Clin Hypertens (Greenwich) 2006, 8:181-186.
8. Münzel T., Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009, 54:1491-1499.
9. Bowen L., Jennings P. Efficacy and safety of nebivolol in patients with stage II hypertension: pooled results from three phase III trials May 3, 2010, New York, NY.
10. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
11. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
12. Everett B.M., Glynn R.J., Danielson E., Ridker P.M. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther 2008, 30:661-672.
13. Flack J.M., Calhoun D.A., Satlin L., et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens 2009, 23:479-489.
14. Jamerson K.A., Nwose O., Jean-Louis L., et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004, 17:495-501.
15. Lacourcière Y., Poirier L., Hebert D., et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 2005, 27:1013-1021.
16. Neutel J.M., Smith D.H., Gradman A.H. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens 2010, 24:64-73.
17. Neutel J.M., Smith D.H., Silfani T.N., et al. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006, 20:255-262.
18. Neutel J.M., Smith D.H., Weber M.A., et al. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) 2005, 7:641-646. quiz 647-648.
19. Prisant L.M. Now or never: optimal antihypertensive therapy in the elderly. Prev Cardiol 2008, 11:201-209.
20. Ruilope L.M., Zanchetti A. Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ Versus Amlodipine in Stage II Hypertensive Patients (VASt) trial. J Renin Angiotensin Aldosterone Syst 2006, 7(Suppl 1):S8-S11.
21. Sharma A., Bagchi A., Kinagi S.B., et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007, 29:2667-2676.
22. Smith T.R., Philipp T., Vaisse B., et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007, 9:355-364.
23. Yarows S.A., Oparil S., Patel S., et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008, 25:1288-1302.
24. Weber M.A., Basile J., Stapff M., et al. Blood pressure effects of combined beta-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens (Greenwich) 2012, 14:588-592.
25. Wald D.S., Law M., Morris J.K., et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009, 122:290-300.
26. Weiss R.J., Saunders E., Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin Ther 2011, 33:1150-1161.
27. Ambrosioni E., Borghi C. Tolerability of nebivolol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension. A meta-analysis. High Blood Pressure Cardiovascular Prevention 2005, 12:27-35.
28. Qureshi A.I., Suri M.F., Kirmani J.F., Divani A.A. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 2005, 11:CR403-CR409.
29. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
30. Bienenfeld L., Frishman W., Glasser S.P. The placebo effect in cardiovascular disease. Am Heart J 1996, 132:1207-1221.
31. Bakris G.L., Lindholm L.H., Black H.R., et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010, 56:824-830.
32. Preston R.A., Materson B.J., Reda D.J., Williams D.W. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study. Arch Intern Med 2000, 160:1449-1454.
33. Law M.R., Wald N.J., Morris J.K., Jordan R.E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326:1427.
34. Germino F.W. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension. Clin Ther 2009, 31:1946-1956.